# US 2020/0392108 A1 · Antibody-drug conjugates and related compounds, compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392108 A1
- Document ID: US20200392108A1
- Status: Published application
- Kind: A1
- Application number: 16/728,045
- Filed: 2019-12-27
- Published: 2020-12-17
- Earliest claimed: 2011-12-05
- Assignees: Magenta Therapeutics, Inc.
- Applicants: Magenta Therapeutics, Inc.
- Inventors: David Y. Jackson; Edward Ha
- Web page: https://patentgrep.com/patent/US20200392108A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/6817: {Toxins}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- C07D 403/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07K 16/32: against translation products of oncogenes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.

## Claims

### Claim 1

An antibody-drug conjugate of the formula:
APD-L-CTX)n
wherein:
A is an antibody,
PD is pyrrole-2,5-dione or pyrrolidine-2,5-dione,
the double bond represents bonds from the 3- and 4-positions of the pyrrole-2,5-dione or pyrrolidine-2,5-dione to the two sulfur atoms of an opened cysteine-cysteine disulfide bond in the antibody,
L is —(CH2)m— or —(CH2CH2O)mCH2CH2—,
CTX is a cytotoxin bonded to L by an amide bond,
n is an integer from 1 to 4, and
m is an integer from 1 to 12.

### Claim 2 (depends on 1)

The antibody-drug conjugate of claim 1, wherein:
A is a monoclonal antibody; or
A is a human or humanized antibody: or
A is an antibody that is specific to a cancer antigen.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The antibody-drug conjugate of claim 1 wherein A is selected from the group consisting of alemtuzumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab, and trastuzumab.

### Claim 6 (depends on 1)

The antibody-drug conjugate of claim 1, wherein A is trastuzumab.

### Claim 7 (depends on 1)

The antibody-drug conjugate of claim 1, wherein CTX is selected from the group consisting of an auristatin, a calicheamicin, a aytansinoid, and a tubulysin.

### Claim 8 (depends on 7)

The antibody-drug conjugate of claim 7, wherein CTX is selected from the group consisting of monomethylauristatin E, monomethylauristatin F, calicheamicin γ, mertansine, tubulysin T3, and tubulysin T4.

### Claim at position 8

9-12. (canceled)

### Claim 13 (depends on 1)

A pharmaceutical composition containing an antibody-drug conjugate of claim 1.

### Claim 14 (depends on 1)

A method of treating a cancer, the method comprising administering to a human suffering therefrom an effective amount of the antibody-drug conjugate of claim 1.

### Claim 15

A linker-cytotoxin conjugate of formula A, B, or C:
wherein R is C1-6 alkyl, optionally substituted with halo or hydroxyl; phenyl, optionally substituted with halo, hydroxyl, carboxyl, C1-3 alkoxycarbonyl, or C1-3 alkyl; naphthyl, optionally substituted with halo, hydroxyl, carboxyl, C1-3 alkoxycarbonyl, or C1-3 alkyl; or 2-pyridyl, optionally substituted with halo, hydroxyl, carboxyl, C1-3 alkoxycarbonyl, or C1-3 alkyl,
L is —(CH2)m— or —(CH2CH2O)mCH2CH2—,
CTX is a cytotoxin bonded to L by an amide bond, and
m is an integer from 1 to 12.

### Claim at position 12

16-24. (canceled)

### Claim 25

A linker of formula AA, BB, or CC:
wherein R is C1-6 alkyl, optionally substituted with halo or hydroxyl; phenyl, optionally substituted with halo, hydroxyl, carboxyl, C1-3 alkoxycarbonyl, or C1-3 alkyl; naphthyl, optionally substituted with halo, hydroxyl, carboxyl, C1-3 alkoxycarbonyl, or C1-3 alkyl; or 2-pyridyl, optionally substituted with halo, hydroxyl, carboxyl, C1-3 alkoxycarhonyl, or C1-3 alkyl,
L is —(CH2)m— or —(CH2CH2O)mCH2CH2—,
Z is carboxyl, C1-6 alkoxycarbonyl, or amino, and
m is an integer from 1 to 12.

### Claim at position 14

26-34. (canceled)

### Claim 35

A linker of formula AAA, BBB, or CCC:
wherein R′ is chloro, bromo, iodo, C1-6 alkylsulfonyloxy, trifluoromethanesulfonyloxy, benzenesulfonyloxy, or 4-toluenesulfonyloxy,
L is —(CH2)m— or —(CH2CH2O)mCH2CH2—,
Z is carboxyl, C1-6 alkoxycarhonyl, or amino, and
m is an integer from 1 to 12.

### Claim at position 16

36-45. (canceled)

### Claim 46

A tubulysin compound of the formula T3:
or a tubulysin compound of the formula T4:

### Claim 47

(canceled)
